Therapeutic use of Aldara™ in chronic myeloid leukemia

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Marleau, Annette M ^a   Lipton, Jeffrey H ^b   Riordan, Neil H ^a   Ichim, Thomas E ^a  

^a MediStem Laboratories Inc   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BCR ABL PROTEIN; BUSULFAN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 2; ISATORIBINE; LEUKEMIA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLACEBO; RESIQUIMOD; ROQUINIMEX; TOLL LIKE RECEPTOR 7; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ABSENCE OF SIDE EFFECTS; ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; CANCER INHIBITION; CANCER PATIENT; CELL CLONE; CELL MATURATION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONDYLOMA; CREAM; DENDRITIC CELL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; SKIN IRRITATION; T LYMPHOCYTE ACTIVATION; DRUG EFFECT; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; HUMANS; IMMUNITY, INNATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 33847001277     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-4     Document Type: Review

References (108)

1. Randolph TR Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy Clin Lab Sci 2005 18 49-56 15747786
2. Hehlmann R Current CML therapy: Progress and dilemma Leukemia 2003 17 1010-1012 10.1038/sj.leu.2402951 12764362
3. Saglio G Cilloni D Rancati F Boano L Glivec and CML: A lucky date J Biol Regul Homeost Agents 2004 18 246-251 15739279
4. Talpaz M Silver RT Druker BJ Goldman JM Gambacorti-Passerini C Guilhot F Schiffer CA Fischer T Deininger MW Lennard AL Hochhaus A Ottmann OG Gratwohl A Baccarani M Stone R Tura S Mahon FX Fernandes-Reese S Gathmann I Capdeville R Kantarjian HM Sawyers CL Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study Blood 2002 99 1928-1937 10.1182/blood.V99.6.1928 11877262
5. Sawyers CL Hochhaus A Feldman E Goldman JM Miller CB Ottmann OG Schiffer CA Talpaz M Guilhot F Deininger MW Fischer T O'Brien SG Stone RM Gambacorti-Passerini CB Russell NH Reiffers JJ Shea TC Chapuis B Coutre S Tura S Morra E Larson RA Saven A Peschel C Gratwohl A Mandelli F Ben-Am M Gathmann I Capdeville R Paquette RL Druker BJ Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study Blood 2002 99 3530-3539 10.1182/blood.V99.10.3530 11986204
6. Lahaye T Riehm B Berger U Paschka P Muller MC Kreil S Merx K Schwindel U Schoch C Hehlmann R Hochhaus A Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up Cancer 2005 103 1659-1669 10.1002/ cncr.20922 15747376
7. Gadzicki D von Neuhoff N Steinemann D Just M Busche G Kreipe H Wilkens L Schlegelberger B BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib Cancer Genet Cytogenet 2005 159 164-167 10.1016/j.cancergencyto.2004.09.021 15899391
8. Rumpold H Wolf AM Gruenewald K Gastl G Gunsilius E Wolf D RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines Exp Hematol 2005 33 767-775 10.1016/j.exphem.2005.03.014 15963852
9. le Coutre P Kreuzer KA Na IK Lupberger J Holdhoff M Appelt C Schwarz M Muller C Gambacorti-Passerini C Platzbecker U Bonnet R Ehninger G Schmidt CA Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571 Blood Cells Mol Dis 2002 28 75 85 10.1006/bcmd.2002.0493 11987244
10. Mathe G Amiel JL Schwarzenberg L Hayat M Pouillart P Schneider M Cattan A Jasmin C Belpomme D Schlumberger JR De Vassal F Musset M Misset JL [Active immunotherapy of acute leukemia and leukemic lymphosarcoma. Results of 10 years. Study of 200 cases] Nouv Presse Med 1975 4 1337-1342 1098015
11. Powles RL Russell J Lister TA Oliver T Whitehouse JM Malpas J Chapuis B Crowther D Alexander P Immunotherapy for acute myelogenous leukaemia: A controlled clinical study 2 1/2 years after entry of the last patient Br J Cancer 1977 35 265-272 322689
12. Foon KA Smalley RV Riggs CW Gale RP The role of immunotherapy in acute myelogenous leukemia Arch Intern Med 1983 143 1726-1731 10.1001/ archinte.143.9.1726 6577818
13. Ramachandar K Baker MA Taub RN Antibody responses to leukemia-associated antigens during immunotherapy of chronic myelocytic leukemia Blood 1975 46 845-854 1060471
14. Advani SH Gulwani B Ghogale SG Shetye MR Gangal SG Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia Oncology 1985 42 275-281 3897932
15. Izquierdo J Robbio ER Lozzio BB Hanna W Immunotherapy of human leukemia with antibody to pluripotential K-562 stem cells J Cancer Res Clin Oncol 1983 105 83-93 10.1007/BF00391837 6403549
16. Chen W Peace DJ Rovira DK You SG Cheever MA T-cell immunity to the joining region of p210BCR-ABL protein Proc Natl Acad Sci U S A 1992 89 1468-1472 48472 1346932 10.1073/pnas.89.4.1468
17. Bocchia M Wentworth PA Southwood S Sidney J McGraw K Scheinberg DA Sette A Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules Blood 1995 85 2680-2684 7742526
18. Bocchia M Korontsvit T Xu Q Mackinnon S Yang SY Sette A Scheinberg DA Specific human cellular immunity to bcr-abl oncogene-derived peptides Blood 1996 87 3587-3592 8611681
19. Posthuma EF Falkenburg JH Apperley JF Gratwohl A Roosnek E Hertenstein B Schipper RF Schreuder GM D'Amaro J Oudshoorn M van Biezen JH Hermans J Willemze R Niederwieser D HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT Blood 1999 93 3863-3865 10339494
20. Posthuma EF Falkenburg JH Apperley JF Gratwohl A Hertenstein B Schipper RF Oudshoorn M Biezen JH Hermans J Willemze R Roosnek E Niederwieser D HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry Leukemia 2000 14 859-862 10.1038/sj.leu.2401774 10803518
21. Vojvodic S Belic B Popovic S [Association between HLA antigens and leukemia in the population of Vojvodina] Med Pregl 2001 54 128-134 11759203
22. Barrett J Guimaraes A Cullis J Goldman JM Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia Stem Cells 1993 11 Suppl 3 104-108 8298471
23. Bosch GJ Joosten AM Kessler JH Melief CJ Leeksma OC Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide Blood 1996 88 3522-3527 8896419
24. Delforge M Boogaerts MA McGlave PB Verfaillie CM BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal Blood 1999 93 284-292 9864172
25. Lee PP Yee C Savage PA Fong L Brockstedt D Weber JS Johnson D Swetter S Thompson J Greenberg PD Roederer M Davis MM Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat Med 1999 5 677-685 10.1038/9525 10371507
26. Coleman S Fisher J Hoy T Burnett AK Lim SH Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia Leukemia 1996 10 483-487 8642866
27. Giralt S Hester J Huh Y Hirsch-Ginsberg C Rondon G Seong D Lee M Gajewski J Van Besien K Khouri I Mehra R Przepiorka D Korbling M Talpaz M Kantarjian H Fischer H Deisseroth A Champlin R CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Blood 1995 86 4337-4343 7492795
28. Bertazzoli C Marchesi E Passoni L Barni R Ravagnani F Lombardo C Corneo GM Pioltelli P Pogliani E Gambacorti-Passerini C Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients Clin Cancer Res 2000 6 1931-1935 10815918
29. Molldrem JJ Lee PP Wang C Felio K Kantarjian HM Champlin RE Davis MM Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat Med 2000 6 1018-1023 10.1038/79526 10973322
30. Reuben JM Lee BN Johnson H Fritsche H Kantarjian HM Talpaz M Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha Clin Cancer Res 2000 6 1671-1677 10815885
31. Molldrem JJ Lee PP Kant S Wieder E Jiang W Lu S Wang C Davis MM Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells J Clin Invest 2003 111 639-647 151894 12618518 10.1172/JCI200316398
32. Zhai Y Shen XD O'Connell R Gao F Lassman C Busuttil RW Cheng G Kupiec-Weglinski JW Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway J Immunol 2004 173 7115-7119 15585830
33. Shishido T Nozaki N Yamaguchi S Shibata Y Nitobe J Miyamoto T Takahashi H Arimoto T Maeda K Yamakawa M Takeuchi O Akira S Takeishi Y Kubota I Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction Circulation 2003 108 2905-2910 10.1161/ 01.CIR.0000101921.93016.1C 14656915
34. Huang B Zhao J Li H He KL Chen Y Chen SH Mayer L Unkeless JC Xiong H Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Res 2005 65 5009-5014 10.1158/0008-5472.CAN-05-0784 15958541
35. Kakita T Sasada M Moriguchi T Nishimura T Yamamoto K Uchino H Lysis of human leukemic cells by monocyte-derived macrophages activated with interferon-gamma and interleukin-2 Jpn J Cancer Res 1989 80 59-64 2496059
36. Dokhelar MC Testa U Vainchenker W Finale Y Tetaud C Salem P Tursz T NK cell sensitivity of the leukemic K 562 cells; effect of sodium butyrate and hemin induction J Immunol 1982 128 211-216 7033373
37. Karre K Ljunggren HG Piontek G Kiessling R Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy Nature 1986 319 675-678 10.1038/319675a0 3951539
38. Moretta A Vitale M Bottino C Orengo AM Morelli L Augugliaro R Barbaresi M Ciccone E Moretta L P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities J Exp Med 1993 178 597-604 10.1084/jem.178.2.597 8340759
39. Bauer S Groh V Wu J Steinle A Phillips JH Lanier LL Spies T Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science 1999 285 727-729 10.1126/science.285.5428.727 10426993
40. Smyth MJ Swann J Cretney E Zerafa N Yokoyama WM Hayakawa Y NKG2D function protects the host from tumor initiation J Exp Med 2005 202 583-588 10.1084/jem.20050994 16129707
41. Gasser S Orsulic S Brown EJ Raulet DH The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 2005 436 1186-1190 1352168 15995699 10.1038/nature03884
42. Yang J Yu Y Hamrick HE Duerksen-Hughes PJ ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses Carcinogenesis 2003 24 1571-1580 10.1093/carcin/bgg137 12919958
43. Sconocchia G Lau M Provenzano M Rezvani K Wongsena W Fujiwara H Hensel N Melenhorst J Li J Ferrone S Barrett AJ The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions Blood 2005 106 3666-3672 10.1182/ blood-2005-02-0479 16046526
44. Terme M Borg C Guilhot F Masurier C Flament C Wagner EF Caillat-Zucman S Bernheim A Turhan AG Caignard A Zitvogel L BCR/ABL promotes dendritic cell-mediated natural killer cell activation Cancer Res 2005 65 6409-6417 10.1158/0008-5472.CAN-04-2675 16024645
45. Levitt LJ Nagler A Lee F Abrams J Shatsky M Thompson D Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor J Clin Invest 1991 88 67-75 296004 1676038
46. Gibson FM Malkovska V Myint AA Meager A Gordon-Smith EC Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products Exp Hematol 1991 19 659-663 1909968
47. Murphy WJ Keller JR Harrison CL Young HA Longo DL Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo Blood 1992 80 670-677 1379086
48. Teichmann JV Ludwig WD Thiel E Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples Nat Immun 1992 11 117-132 1392400
49. Bendall LJ Kortlepel K Bradstock KF Gottlieb DJ Natural killer cells adhere to bone marrow fibroblasts and inhibit adhesion of acute myeloid leukemia cells Leukemia 1995 9 999-1005 7596192
50. Klingemann HG Eaves CJ Barnett MJ Eaves AC Hogge DE Nantel SH Reece E Shepherd JD Sutherland HJ Phillips GL Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration Bone Marrow Transplant 1994 14 389-396 7994260
51. Tam YK Martinson JA Doligosa K Klingemann HG Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy Cytotherapy 2003 5 259-272 10.1080/14653240310001523 12850795
52. Morecki S Revel-Vilk S Nabet C Pick M Ackerstein A Nagler A Naparstek E Ben Shahar M Slavin S Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2 Cancer Immunol Immunother 1992 35 401-411 10.1007/ BF01789019 1394343
53. Vey N Blaise D Lafage M Olive D Viens P Baume D Camerlo J Stoppa AM Gabus R Brandely M Hercend T Maraninchi D Treatment of chronic myelogenous leukemia with interleukin-2: A phase II study in 21 patients J Immunother 1999 22 175-181 10093042
54. Rowe JM Rapoport AP Ryan DH Nilsson BI Duerst RE Packman CH Abboud CN DiPersio JF Linder T Wang N Simonsson B Liesveld JL Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex Bone Marrow Transplant 1999 24 1057-1063 10.1038/ sj.bmt.1702037 10578155
55. Chang WC Hsiao MH Pattengale PK Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor Nat Immun Cell Growth Regul 1991 10 57-70 1881400
56. Pawelec G Da Silva P Max H Kalbacher H Schmidt H Bruserud O Zugel U Baier W Rehbein A Pohla H Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha Leuk Lymphoma 1995 18 471-478 8528055
57. Li Z Qiao Y Liu B Laska EJ Chakravarthi P Kulko JM Bona RD Fang M Hegde U Moyo V Tannenbaum SH Menoret A Gaffney J Glynn L Runowicz CD Srivastava PK Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia Clin Cancer Res 2005 11 4460-4468 10.1158/1078-0432.CCR-05-0250 15958631
58. Delwail V Meseri A Brizard A Lecron JC Sadoun A Costerousse F Guilhot F Tanzer J Goube de Laforest P Enhanced NK activity during blast crisis in chronic myelogenous leukemia (CML) Leuk Res 1992 16 721-722 10.1016/ 0145-2126(92)90024-2 1635387
59. Goldstein D Hertzog P Tomkinson E Couldwell D McCarville S Parrish S Cunningham P Newell M Owens M Cooper DA Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification J Infect Dis 1998 178 858-861 9728559
60. Witt PL Ritch PS Reding D McAuliffe TL Westrick L Grossberg SE Borden EC Phase I trial of an oral immunomodulator and interferon inducer in cancer patients Cancer Res 1993 53 5176-5180 8221654
61. Savage P Horton V Moore J Owens M Witt P Gore ME A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily Br J Cancer 1996 74 1482-1486 8912549
62. http://www.aldara.com
63. Lee PK Harwell WB Loven KH Phillips TJ Whiting DA Andres KL Lee JH Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream Dermatol Surg 2005 31 659-664 15996416
64. Ooi T Barnetson RS Zhuang L McKane S Lee JH Slade HB Halliday GM Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial Br J Dermatol 2006 154 72-78 10.1111/ j.1365-2133.2005.06932.x 16403097
65. Quirk C Gebauer K Owens M Stampone P Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks Australas J Dermatol 2006 47 258-265 10.1111/j.1440-0960.2006.00313.x 17034468
66. Arican O Guneri F Bilgic K Karaoglu A Topical imiquimod 5% cream in external anogenital warts: A randomized, double-blind, placebo-controlled study J Dermatol 2004 31 627-631 15492435
67. Hemmi H Kaisho T Takeuchi O Sato S Sanjo H Hoshino K Horiuchi T Tomizawa H Takeda K Akira S Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 2002 3 196-200 10.1038/ni758 11812998
68. Horsmans Y Berg T Desager JP Mueller T Schott E Fletcher SP Steffy KR Bauman LA Kerr BM Averett DR Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection Hepatology 2005 42 724-731 10.1002/hep.20839 16116638
69. Jurk M Heil F Vollmer J Schetter C Krieg AM Wagner H Lipford G Bauer S Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 Nat Immunol 2002 3 499 10.1038/ni0602-499 12032557
70. Chuang TH Ulevitch RJ Cloning and characterization of a sub-family of human toll-like receptors: HTLR7, hTLR8 and hTLR9 Eur Cytokine Netw 2000 11 372-378 11022120
71. Gibson SJ Lindh JM Riter TR Gleason RM Rogers LM Fuller AE Oesterich JL Gorden KB Qiu X McKane SW Noelle RJ Miller RL Kedl RM Fitzgerald-Bocarsly P Tomai MA Vasilakos JP Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod Cell Immunol 2002 218 74-86 10.1016/S0008-8749(02)00517-8 12470615
72. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M: Identification and characterization of pDC-like cells in normal skin and melanomas treated with imiquimod. J Immunol 173:3051-3061.
73. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005, 97:1143-1153.
74. Ebner S, Ehammer Z, Holzmann S, Schwingshackl P, Forstner M, Stoitzner P, Huemer GM, Fritsch P, Romani N: Expression of C type lectin receptors by subsets of dendritic cells in human skin. Int Immunol 2004, 16:877-887.
75. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP: Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005, 174:2476-2480.
76. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, J, Gilboa E: Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. Immunol 2003, 171:6275-6282.
77. Zhang M, Zhang YZ, Wang L, Wang S, Li FY: [The relation of local status to efficacy of immunotherapy in patients with condyloma acuminatum]. Sichuan Da Xue Xue Bao Yi Xue Ban 2005, 36:559-561.
78. van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH: Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005, 11:5273-5280.
79. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M: Immune response modifiers--mode of action. Exp Dermatol 2006, 15:331-341.
80. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. 1997, 89:1133-1142.
81. Kolb HJ, Rank A, Chen X, Woiciechowsky A, Roskrow M, Schmid C, J, Ledderose G: In-vivo generation of leukaemiaderived dendritic cells. Best Pract Res Clin Haematol 2004, 17:439-451.
82. Lore K. Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, Koup RA: Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV- 1-specific T cell responses. J Immunol 2003, 171:4320-4328.
83. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF: TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005, 175:1983-1990.
84. Harrison CJ, Miller RL, Bernstein DI: Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001, 19:1820-1826.
85. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95:1781-1787.
86. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103:1037-1042.
87. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F: Effect of a p210 multipeptide vaccine associated with imatinib interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005, 365:657-662.
88. Johnson JG, Jenkins MK: The role of anergy in peripheral T cell unresponsiveness. Life Sci 1994, 55:1767-1780.
89. Wells AD, Walsh MC, Bluestone JA, Turka LA: Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001, 108:895-903.
90. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ: immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000,203:55-65.
91. Slade HB, Owens ML, Tomai MA, Miller RL: Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs 1998, 7:437-449.
92. Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, E, Bell DA, Min WP: Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003, 171:691-696.
93. Becker JC, Czerny C, Brocker EB: Maintenance of clonal anergy endogenously produced IL-10. Int Immunol 1994, 6:1605-1612.
94. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y: Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma 2005, 46:935-939.
95. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005, 174:8210-8218.
96. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ: Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005, 335:1293-1304.
97. Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, Alyea EP, Kantoff P, Soiffer RJ, Dranoff G, Ritz J: CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2001, 98:7492-7497.
98. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S: Donor type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
99. Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med 2005, 172:1434-1439.
100. Nomura T, Sakaguchi S: Naturally arising CD25+CD4+ regulatory in tumor immunity. Curr Top Microbiol Immunol 2005, 293:287-302.
101. Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H: Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 2005, 102:9253-9257.
102. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside Immune responses to p53 in patients with cancer: Enrichment tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005, 54:1072-1081.
103. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, WG: Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005, 19:1788-1793.
104. Jones E, Golgher D, Simon AK, Dahm-Vicker M, Screaton G, Elliott T, Gallimore A: The influence of CD25+ cells on the generation immunity to tumour cell lines in mice. Novartis Found Symp 256:149-52; discussion 152-7, 259-69.
105. Pasare C, Medzhitov R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
106. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
107. Helg C, Starobinski M, Jeannet M, Chapuis B: Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998, 29:301-313.
108. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA: Tumor regression and autoimmunity patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005, 12:1005-1016.